Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 30, 2025

B16-MO4

RRID:CVCL_WM78

Type: Cell Line

Proper Citation

(RRID:CVCL_WM78)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_WM78

Proper Citation: (RRID:CVCL_WM78)

Sex: Male

Defining Citation: PMID:7585145

Comments: Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1

(Millipore=SCC420).

Category: Cancer cell line

Name: B16-MO4

Synonyms: B16-OVA M04, B16-OVA MO4, B16 clone M04, M04, M04

Cross References: BioGRID_ORCS_Cell_line:1264, Millipore:SCC420,

Wikidata:Q93328141

ID: CVCL WM78

Record Creation Time: 20250131T193954+0000

Record Last Update: 20250131T194219+0000

Ratings and Alerts

No rating or validation information has been found for B16-MO4.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 261 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Hernandez-Franco JF, et al. (2024) Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity. NPJ vaccines, 9(1), 149.

Ginefra P, et al. (2024) Urolithin-A Promotes CD8+ T Cell-mediated Cancer Immunosurveillance via FOXO1 Activation. Cancer research communications, 4(5), 1189.

Colombani T, et al. (2023) Hypoxia-inducing cryogels uncover key cancer-immune cell interactions in an oxygen-deficient tumor microenvironment. bioRxiv: the preprint server for biology.

Chen Z, et al. (2023) An mRNA vaccine elicits STING-dependent antitumor immune responses. Acta pharmaceutica Sinica. B, 13(3), 1274.

Jiang H, et al. (2023) Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity. Cancer research communications, 3(6), 1118.

Di Trani CA, et al. (2023) Intracavitary adoptive transfer of IL-12 mRNA-engineered tumorspecific CD8+ T cells eradicates peritoneal metastases in mouse models. Oncoimmunology, 12(1), 2147317.

Xiao J, et al. (2023) UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer. The Journal of clinical investigation, 133(4).

Fox DB, et al. (2023) Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. NPJ precision oncology, 7(1), 25.

Zhang T, et al. (2023) CCDC134 facilitates T cell activation through the regulation of early T cell receptor signaling. Frontiers in immunology, 14, 1133111.

Cheng H, et al. (2023) Extracellular acidosis restricts one-carbon metabolism and preserves T cell stemness. Nature metabolism, 5(2), 314.

Arra A, et al. (2023) PD-1 limits differentiation and plasticity of Tc17 cells. Frontiers in immunology, 14, 1104730.

Xu W, et al. (2023) GOT1 regulates CD8+ effector and memory T cell generation. Cell reports, 42(1), 111987.

Sun W, et al. (2023) Monocytes reprogrammed by tumor microparticle vaccine inhibit tumorigenesis and tumor development. Cancer nanotechnology, 14(1), 34.

Joachim L, et al. (2023) The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors. EBioMedicine, 97, 104834.

Popovi? B, et al. (2023) Time-dependent regulation of cytokine production by RNA binding proteins defines T cell effector function. Cell reports, 42(5), 112419.

Tamura Y, et al. (2023) A Sulfur Containing Melanogenesis Substrate, N-Pr-4-S-CAP as a Potential Source for Selective Chemoimmunotherapy of Malignant Melanoma. International journal of molecular sciences, 24(6).

Battistello E, et al. (2023) Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion. Molecular cell, 83(8), 1216.

Li J, et al. (2023) Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines. Chemical engineering journal (Lausanne, Switzerland: 1996), 456, 140930.

Boreel DF, et al. (2023) Quantitative Imaging of Hypoxic CAIX-Positive Tumor Areas with Low Immune Cell Infiltration in Syngeneic Mouse Tumor Models. Molecular pharmaceutics, 20(4), 2245.

Olivera I, et al. (2023) mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. Cell reports. Medicine, 4(3), 100978.